Trials / Completed
CompletedNCT00274690
Post-Operative Nausea And Vomiting Study In Female Patients
A Multicenter, Randomised, Double-blind, Placebo-controlled, Parallel Group, Phase II Study to Evaluate the Safety and Efficacy of Oral Dosing With GW679769 (50 mg or 150 mg) for Three Consecutive Days When Administered With a Single Intravenous Dose of Ondansetron Hydrochloride for the Prevention of Post-operative Nausea and Vomiting and Post-discharge Nausea and Vomiting in Female Subjects With Known Risk Factors for Post-operative Nausea and Vomiting Who Are Undergoing Laparoscopic/Laparotomic Surgical Procedures Associated With an Increased Emetogenic Risk
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 435 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- Female
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study is to determine an effective dose of this NK-1 anti-emetic medication to prevent nausea and vomiting in females after surgery.
Detailed description
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase II Study to Evaluate the Safety and Efficacy of Oral Dosing with GW679769 (50 mg or 150 mg) for Three Consecutive Days When Administered with a Single Intravenous Dose of Ondansetron Hydrochloride for the Prevention of Post-operative Nausea and Vomiting and Post-discharge Nausea and Vomiting in Female Subjects with Known Risk Factors for Post-operative Nausea and Vomiting Who are Undergoing Laparoscopic/Laparotomic Surgical Procedures Associated with an Increased Emetogenic Risk
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GW679769 |
Timeline
- Start date
- 2005-02-01
- Primary completion
- 2005-08-01
- Completion
- 2005-08-01
- First posted
- 2006-01-11
- Last updated
- 2017-01-20
Locations
44 sites across 11 countries: United States, Denmark, Hong Kong, Hungary, Israel, Norway, Philippines, Slovenia, Spain, Thailand, United Kingdom
Source: ClinicalTrials.gov record NCT00274690. Inclusion in this directory is not an endorsement.